Praxis Precision Medicines, Inc.
PRAX
Classifica tra le azioni
#2756
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Prezzo delle azioni
$244.57
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$6.83B
Variazione (1 giorno)
-1.48%
Variazione (1 anno)
28.73%
Paese
US
Scambia Praxis Precision Medicines, Inc. (PRAX)
Categoria
Healthcare
EPS per Praxis Precision Medicines, Inc. (PRAX)
EPS al June 2026 TTM: $-12.95
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Praxis Precision Medicines, Inc., l’EPS attuale della società (TTM) è $-12.95. Alla fine del 2023, la società aveva un EPS di $-18.69 una diminuzione rispetto a rispetto a quello del 2022, che era di $-69.33.
Storico EPS per Praxis Precision Medicines, Inc. da 2018 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-12.95 | 26.84% |
| 2024 | $-10.21 | -45.37% |
| 2023 | $-18.69 | -73.04% |
| 2022 | $-69.33 | 17.59% |
| 2021 | $-58.96 | -43.09% |
| 2020 | $-103.61 | -70.25% |
| 2019 | $-348.24 | 13.53% |
| 2018 | $-306.73 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -233.75% |
US
|
|
| $-7.98 | -38.38% |
US
|
|
| $-5.29 | -59.15% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -314.21% |
NL
|
